Results 41 to 50 of about 13,549 (163)
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Haematologica, 2019 Twice-weekly carfilzomib is approved at 27 and 56 mg/m2 to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m 2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients in ...Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, Alessandra Larocca +17 moredoaj +1 more sourceTargeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal +5 morewiley +1 more sourceCarfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma [PDF]
, 2019 International audienceCarfilzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM).Mezzi, Khalid, Mezzi, K., Andrzej Jakubowiak, Ola Landgren, Iskander, K.S., Karim S. Iskander, Sonneveld, Pieter, Landgren, O., Mohamad Mohty, Landgren, O, Mezzi, K, Jakubowiak, Andrzej, Sonneveld, P. (Pieter), Jakubowiak, A, David S. Siegel, Khalid Mezzi, Landgren, Ola, Mohty, M, Pieter Sonneveld, Iskander, Karim, Siegel, David, Iskander, KS, Mohty, Mohamad, Mohty, M. (Mohamad), Siegel, DS, Landgren, Carl +25 morecore +1 more sourceElectrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and Carfilzomib
Frontiers in Drug DiscoveryBackground and PurposeBortezomib and Carfilzomib are first- and second-generation proteasome inhibitors that revolutionized the treatment of multiple myelomas. Despite their efficacy, they have been associated with off-target adverse events.Dario Melgari, Serena Calamaio, Anthony Frosio, Rachele Prevostini, Alessio Malacrida, Alessio Malacrida, Luigi Anastasia, Luigi Anastasia, Carlo Pappone, Carlo Pappone, Gabriella Nicolini, Gabriella Nicolini, Gabriella Nicolini, Guido Cavaletti, Guido Cavaletti, Guido Cavaletti, Ilaria Rivolta, Ilaria Rivolta +17 moredoaj +1 more sourceCardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
Frontiers in Cardiovascular Medicine, 2021 Background: Carfilzomib, an effective proteasome inhibitor agent for the therapy of relapsed and refractory multiple myeloma, has been related to a significant number of cardiovascular events.Yinghong Zhai, Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yang Cao, Zhen Lin, Xiang Zhou, Xiang Zhou, Zhijian Guo, Jia He, Jia He +12 moredoaj +1 more sourceOvercoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas
Molecular Oncology, EarlyView.Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek +20 morewiley +1 more sourceCarfilzomib‐induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study
, 2020 OBJECTIVE: Hemolysis is a sporadically reported but potentially serious side effect of the proteasome inhibitor carfilzomib. We aimed to investigate the frequency of hemolysis in an unselected cohort.METHODS: We performed a retrospective, single-center ...Bertil Uggla, Piotr Kozlowski, Maria Åström, Kameran Behnam, Klodia,, Uggla, Bertil,, Klodia Kameran Behnam, Kozlowski, Piotr,, Åström, Maria, +7 morecore +1 more sourceNear‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease
Advanced Science, EarlyView.Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li +11 morewiley +1 more sourcePharmacokinetic parameters of carfilzomib after the intravenous administration of polymeric micelle formulation containing carfilzomib (CFZ-PM) and cyclodextrin-based carfilzomib formulation (CFZ-CD) to ICR mice.
, 2017 Pharmacokinetic parameters of carfilzomib after the intravenous administration of polymeric micelle formulation containing carfilzomib (CFZ-PM) and cyclodextrin-based carfilzomib formulation (CFZ-CD) to ICR mice.Heon-Min Ryu (3821398), Shin-Hyung Park (795169), Gongmi Ryoo (3821383), Ho-Young Lee (1612351), Su-Chan Lee (2008804), Kyung Bo Kim (455781), Soo Kyung Bae (451734), Derek Reichel (3821386), Songhee Han (1363716), Ji Eun Park (455778), Jee Sun Min (3821395), Younsoo Bae (2179982), Yunseok Oh (3821392), Wooin Lee (455782), Se-Eun Chun (3821389) +14 morecore +1 more sourceInsulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
Biomolecules, 2022 Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. This drug is considered to be extremely specific in inhibiting the chymotrypsin-like activity of the 20S ...Grazia Raffaella Tundo, Diego Sbardella, Francesco Oddone, Giuseppe Grasso, Stefano Marini, Maria Grazia Atzori, Anna Maria Santoro, Danilo Milardi, Francesco Bellia, Gabriele Macari, Grazia Graziani, Fabio Polticelli, Paolo Cascio, Mariacristina Parravano, Massimo Coletta +14 moredoaj +1 more source
